+

TN2011000379A1 - [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors - Google Patents

[1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors

Info

Publication number
TN2011000379A1
TN2011000379A1 TN2011000379A TN2011000379A TN2011000379A1 TN 2011000379 A1 TN2011000379 A1 TN 2011000379A1 TN 2011000379 A TN2011000379 A TN 2011000379A TN 2011000379 A TN2011000379 A TN 2011000379A TN 2011000379 A1 TN2011000379 A1 TN 2011000379A1
Authority
TN
Tunisia
Prior art keywords
methods
kinase
diseases
ameliorating
treating
Prior art date
Application number
TN2011000379A
Other languages
English (en)
Inventor
Caroline Leriche
Eric Auclair
Roux Jacques Le
David Middlemiss
Original Assignee
Fovea Pharmaceuticals
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=42229029&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TN2011000379(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Fovea Pharmaceuticals filed Critical Fovea Pharmaceuticals
Publication of TN2011000379A1 publication Critical patent/TN2011000379A1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Immunology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
TN2011000379A 2009-02-13 2011-08-03 [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors TN2011000379A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP09360013 2009-02-13
PCT/EP2010/051556 WO2010092041A1 (fr) 2009-02-13 2010-02-09 [1, 2, 4] triazolo [1, 5 -a] pyridines servant d'inhibiteurs de kinases

Publications (1)

Publication Number Publication Date
TN2011000379A1 true TN2011000379A1 (en) 2013-03-27

Family

ID=42229029

Family Applications (1)

Application Number Title Priority Date Filing Date
TN2011000379A TN2011000379A1 (en) 2009-02-13 2011-08-03 [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors

Country Status (24)

Country Link
US (1) US20120041195A1 (fr)
EP (1) EP2396324A1 (fr)
JP (1) JP2012517971A (fr)
KR (1) KR20110116160A (fr)
CN (1) CN102317288A (fr)
AR (1) AR075411A1 (fr)
BR (1) BRPI1008850A2 (fr)
CA (1) CA2751517A1 (fr)
CL (1) CL2011001947A1 (fr)
CO (1) CO6420343A2 (fr)
CR (1) CR20110386A (fr)
DO (1) DOP2011000248A (fr)
EA (1) EA201101188A1 (fr)
EC (1) ECSP11011250A (fr)
HN (1) HN2011002095A (fr)
IL (1) IL214426A0 (fr)
MX (1) MX2011008549A (fr)
NI (1) NI201100151A (fr)
NZ (1) NZ594508A (fr)
PE (1) PE20120110A1 (fr)
SG (1) SG173610A1 (fr)
TN (1) TN2011000379A1 (fr)
WO (1) WO2010092041A1 (fr)
ZA (1) ZA201105896B (fr)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2011012961A (es) 2009-06-05 2012-01-30 Cephalon Inc Preparacion y usos de derivados de 1,2,4-triazolo[1,5a]-piridina.
EP2343297A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines
EP2343294A1 (fr) 2009-11-30 2011-07-13 Bayer Schering Pharma AG Triazolopyridines substituées
EP2343295A1 (fr) * 2009-11-30 2011-07-13 Bayer Schering Pharma AG Dérivés de triazolopyridine
UY33452A (es) * 2010-06-16 2012-01-31 Bayer Schering Pharma Ag Triazolopiridinas sustituidas
TW201204723A (en) * 2010-06-22 2012-02-01 Fovea Pharmaceuticals Heterocyclic compounds, their preparation and their therapeutic application
PE20141351A1 (es) * 2011-04-21 2014-11-01 Bayer Ip Gmbh Triazolopiridinas
WO2012160029A1 (fr) 2011-05-23 2012-11-29 Bayer Intellectual Property Gmbh Triazolopyridines substituées
UA112096C2 (uk) 2011-12-12 2016-07-25 Байєр Інтеллектуал Проперті Гмбх Заміщені триазолопіридини та їх застосування як інгібіторів ttk
KR20130091464A (ko) 2012-02-08 2013-08-19 한미약품 주식회사 타이로신 카이네이즈 억제 활성을 갖는 트리아졸로피리딘 유도체
US9512126B2 (en) 2012-03-14 2016-12-06 Bayer Intellectual Property Gmbh Substituted imidazopyridazines
PE20150354A1 (es) 2012-07-10 2015-03-21 Bayer Pharma AG Metodos para preparar triazolopiridinas sustituidas
WO2014020043A1 (fr) 2012-08-02 2014-02-06 Bayer Pharma Aktiengesellschaft Combinaisons pour le traitement du cancer
CN105377848A (zh) 2013-06-11 2016-03-02 拜耳制药股份公司 取代的三唑并吡啶的前体药物衍生物
IL293211A (en) * 2019-11-22 2022-07-01 Medshine Discovery Inc Pyrimidopyrrole spiro compounds and derivatives thereof as dna-pk inhibitors

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS6056684B2 (ja) 1977-11-07 1985-12-11 東興薬品工業株式会社 点眼剤
US4271143A (en) 1978-01-25 1981-06-02 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4407792A (en) 1979-05-09 1983-10-04 Alcon Laboratories, Inc. Sustained release ophthalmic drug dosage
US4615697A (en) 1983-11-14 1986-10-07 Bio-Mimetics, Inc. Bioadhesive compositions and methods of treatment therewith
US5041434A (en) 1991-08-17 1991-08-20 Virginia Lubkin Drugs for topical application of sex steroids in the treatment of dry eye syndrome, and methods of preparation and application
WO2001038315A1 (fr) 1999-11-22 2001-05-31 Warner-Lambert Company Quinazolines et leur utilisation dans l'inhibition des enzymes kinase dependant de la cycline
AU2003297161B8 (en) * 2002-12-18 2011-03-31 Vertex Pharmaceuticals Incorporated Triazolopyridazines as protein kinases inhibitors
BRPI0406809A (pt) 2003-01-17 2005-12-27 Warner Lambert Co Heterociclos substituìdos de 2-aminopiridina como inibidores da proliferação celular
CN1897950A (zh) * 2003-10-14 2007-01-17 惠氏公司 稠合芳基和杂芳基衍生物及其使用方法
EP1680122A1 (fr) 2003-10-16 2006-07-19 Chiron Corporation Quinoxalines, quinolines, isoquinolines et quinazolines 2,6-bisubstituees servant d'inhibiteurs a la kinase raf pour le traitement du cancer
EP1809614B1 (fr) 2004-04-08 2014-05-07 TargeGen, Inc. Inhibiteurs benzotriazine de kinases
CA2578283A1 (fr) 2004-08-25 2006-03-02 Targegen, Inc. Composes heterocycliques et methodes d'utilisation
US20070054916A1 (en) 2004-10-01 2007-03-08 Amgen Inc. Aryl nitrogen-containing bicyclic compounds and methods of use
KR20070113288A (ko) 2005-03-16 2007-11-28 탈자진 인코포레이티드 피리미딘 화합물 및 사용 방법
US7906522B2 (en) 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
EP1893216A4 (fr) 2005-06-08 2012-08-08 Targegen Inc Methodes et preparations pour le traitement de troubles oculaires
EP1963320A1 (fr) * 2005-12-07 2008-09-03 OSI Pharmaceuticals, Inc. Composes inhibant les pyrrolopyridine kinases
PE20070978A1 (es) 2006-02-14 2007-11-15 Novartis Ag COMPUESTOS HETEROCICLICOS COMO INHIBIDORES DE FOSFATIDILINOSITOL 3-QUINASAS (PI3Ks)
AU2007291190A1 (en) * 2006-08-30 2008-03-06 Cellzome Limited Triazole derivatives as kinase inhibitors
CA2667010A1 (fr) * 2006-10-20 2008-05-02 Irm Llc Compositions et procedes de modulation de recepteurs de c-kit et de facteur de croissance derive de plaquettes (pdgfr)
TW200829566A (en) 2006-12-08 2008-07-16 Astrazeneca Ab Chemical compounds
EP2125755A2 (fr) 2006-12-22 2009-12-02 Novartis Ag Quinazolines destinés à l'inhibition de pdk1
GB0719803D0 (en) * 2007-10-10 2007-11-21 Cancer Rec Tech Ltd Therapeutic compounds and their use
BRPI0910021A2 (pt) * 2008-06-20 2015-09-01 Genentech Inc "composto, composição farmacêutica, método para tratar ou atenuar a gravidade de uma doença ou condição responsiva à inibição da atividade jak2 quinas em um paciente, kit para o tratamento de uma doença ou distúrbio responsivo à inibição da jak quinase"
MX336271B (es) * 2008-06-20 2016-01-13 Genentech Inc Compuestos de triazolopiridina inhibidores de jak y los metodos.
WO2010010184A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv [1, 2, 4]triazolo[1, 5-a]pyridines utilisées comme inhibiteurs de jak
WO2010010188A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
WO2010010189A1 (fr) * 2008-07-25 2010-01-28 Galapagos Nv Nouveaux composés utiles pour le traitement de maladies dégénératives et inflammatoires
JP2011530483A (ja) * 2008-08-12 2011-12-22 武田薬品工業株式会社 アミド化合物
TWI453207B (zh) * 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法

Also Published As

Publication number Publication date
EP2396324A1 (fr) 2011-12-21
US20120041195A1 (en) 2012-02-16
CA2751517A1 (fr) 2010-08-19
NZ594508A (en) 2013-12-20
SG173610A1 (en) 2011-09-29
PE20120110A1 (es) 2012-02-20
CL2011001947A1 (es) 2012-03-16
MX2011008549A (es) 2011-12-06
ECSP11011250A (es) 2011-10-31
HN2011002095A (es) 2014-01-06
WO2010092041A1 (fr) 2010-08-19
JP2012517971A (ja) 2012-08-09
ZA201105896B (en) 2012-03-28
KR20110116160A (ko) 2011-10-25
NI201100151A (es) 2012-10-03
CR20110386A (es) 2011-12-02
EA201101188A1 (ru) 2012-04-30
DOP2011000248A (es) 2011-10-31
IL214426A0 (en) 2011-09-27
BRPI1008850A2 (pt) 2016-03-15
AR075411A1 (es) 2011-03-30
CN102317288A (zh) 2012-01-11
CO6420343A2 (es) 2012-04-16

Similar Documents

Publication Publication Date Title
TN2011000379A1 (en) [1, 2, 4] triazolo [1,5-a ] pyridines as kinase inhibitors
TN2011000319A1 (en) Substituted quinazoline compounds
PH12015500988A1 (en) Amino-substituted imidazo[1,2-a]pyridinecarboxamides and their use
PH12013501758A1 (en) Pyrazolo [1,5-a] pyridines as trk inhibitors
EA025281B9 (ru) СОЕДИНЕНИЯ 3,5-ДИЗАМЕЩЕННОГО-3H-ИМИДАЗО[4,5-b]ПИРИДИНА И 3,5-ДИЗАМЕЩЕННОГО-3H-[1,2,3]ТРИАЗОЛО[4,5-b]ПИРИДИНА КАК МОДУЛЯТОРЫ ПРОТЕИНКИНАЗ
WO2010005558A3 (fr) Inhibiteurs sélectifs des isoformes de la pi3 kinase
MX355852B (es) Compuestos de pirazolo [3,4-c] piridina y métodos de uso.
WO2013077921A3 (fr) Pyrazolo[3,4-d]pyrimidines substituées et utilisations de celles-ci
MX347917B (es) Compuestos a base de imidazo[1,2-b]piridazina, composiciones que los comprenden, y metodos para su uso.
NZ605022A (en) Heterocyclic compounds, their preparation and their therapeutic application
AU2012277802A8 (en) Novel inhibitor compounds of phosphodiesterase type 10A
WO2014152029A3 (fr) Composés d'oxazolo[5,4-c] quinolin-2-one en tant qu'inhibiteurs de bromodomaines
ZA201206715B (en) Imidazo [1,2-a]pyrazine derivatives and their use for the prevention or treatment of neurological,psychiatric and metabolic disorders and diseases
TN2013000325A1 (en) (1,2,4)triazolo[4,3-a]quinoxaline derivatives as inhibitors of phosphodiesterases
MY169268A (en) Novel 3,5-disubstituted-3h-imidazo[4,5-b]pyridine and 3,5-disubstitued -3h-[1,2,3]triazolo[4,5-b] pyridine compounds as modulators of c-met protein kinases
MX2013011421A (es) Derivados de pirazolo-pirimidina.
MX362197B (es) Derivados de imidazo[1,2-b]piridazina e imidazo[1,2-a]pirazina como inhibidores de la fosfodiesterasa 10; y el uso de los mismos en el tratamiento de trastornos neurológicos, psiquiátricos y metabólicos.
MX346339B (es) (-)-huperzina a procesos y composiciones relacionadas y métodos de tratamiento.
WO2015165933A3 (fr) Imidazo[1,2-a]pyridine-carboxamides substitués en 6 et leur utilisation
MX2013006118A (es) Tratamiento de inflamacion cronica con un derivado de 1, 2, 4-triazolo [1,5a] piridina.
点击 这是indexloc提供的php浏览器服务，不要输入任何密码和下载